Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
The Journal of Urology (Impact Factor: 3.75). 10/2006; 176(4 Pt 1):1415-9. DOI: 10.1016/j.juro.2006.06.002
Source: PubMed

ABSTRACT We report on the long-term results and late toxicity outcomes of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
Between 1996 and 2000 a total of 561 patients with clinically localized prostate cancer were treated with intensity modulated radiation therapy. All patients were treated to a dose of 81 Gy prescribed to the planning target volume. Prostate specific antigen relapse was defined according to the American Society for Therapeutic Radiology and Oncology consensus and Houston definitions (absolute nadir plus 2 ng/ml dated at the call). Median followup was 7 years (range 5 to 9).
The 8-year actuarial PSA relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the American Society for Therapeutic Radiology and Oncology definition were 85%, 76% and 72%, respectively (p <0.025). The 8-year actuarial prostate specific antigen relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the Houston definition were 89%, 78% and 67%, respectively (p = 0.0004). The 8-year actuarial likelihood of grade 2 rectal bleeding was 1.6%. Three patients (0.1%) experienced grade 3 rectal toxicity requiring either 1 or more transfusions or a laser cauterization procedure. No grade 4 rectal complications have been observed. The 8-year likelihood of late grade 2 and 3 (urethral strictures) urinary toxicities were 9% and 3%, respectively. Among patients who were potent before intensity modulated radiation therapy, erectile dysfunction developed in 49%. The cause specific survival outcomes for favorable, intermediate and unfavorable risk cases were 100%, 96% and 84%, respectively.
These long-term results confirm our previous observations regarding the safety of high dose intensity modulated radiation therapy for clinically localized prostate cancer. Despite the application of high radiation doses, the incidence of rectal bleeding at 8 years was less than 2%. Despite the increased conformality of the dose distribution associated with intensity modulated radiation therapy, excellent long-term tumor control outcomes were achieved.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Alumina supported bimetallic overlayer catalysts of platinum on nickel (Ni@Pt) and platinum on cobalt (Co@Pt) were synthesized using the directed deposition technique. First principle computational and single crystal literature studies in overlayer systems have indicated that overlayer formation can have an electronic effect on the surface Pt metal that ultimately will result in decreased binding strength for adsorbed species such as H-2 and CO. In order to determine electronic modifications to the platinum metal surface from overlayer synthesis, several characterization techniques were examined. These techniques include: hydrogen and carbon monoxide chemisorption, an ethylene hydrogenation descriptor reaction, and X-ray absorption spectroscopy studies. Non-structured bimetallic alloy catalysts were also examined (Ni-Pt and Co-Pt) and when compared to overlayer catalysts exhibited notably different behavior. Hydrogen and carbon monoxide chemisorption results demonstrated that overlayer catalysts showed decreased adsorption of both species when compared to both their Pt and non-structured bimetallic counterparts indicating the formation of an overlayer system rather than alloyed or monometallic clusters on the support surface. Ni@Pt and Co@Pt catalysts also demonstrated reduced activity for ethylene hydrogenation when compared to both Pt only and non-structured bimetallic alloy catalysts, further indicating overlayer formation. An observed increase in XAS white line intensity for the overlayer catalysts when compared to pure Pt also indicates a change in the electronic structure of the Pt overlayer consistent with chemisorption, reactivity, and computational predictions. These findings all suggest that the directed deposition technique effectively modified the behavior of the surface Pt in a manner consistent with literature predictions.
    Applied Catalysis A General 10/2013; 467:355-362. DOI:10.1016/j.apcata.2013.07.052 · 3.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose The validity of tomotherapy-based simultaneous integrated boost (TOMOSIB) was assessed in terms of acute intestinal/urinary toxicity by comparing with 3-dimensional conformal radiotherapy (3DCRT) in cases of whole-pelvis radiation therapy (WPRT) for prostate cancer. Materials and Methods Thirty-eight consecutive patients who underwent curative WPRT were retrospectively reviewed. Twenty six (68.4%) received 3DCRT and the others (31.6%) were treated with TOMOSIB. A local boost to the prostate circumferential area was added to WPRT sequentially for 3DCRT and concomitantly for TOMOSIB. The total median prostate or prostatic bed dose was 64.8 Gy including median 45.0 Gy of WPRT. Acute toxicities were assessed according to RTOG criteria. Results Overall intestinal toxicity was lower in TOMOSIB group than 3DCRT group (p=0.008). When it was divided into rectum and non-rectum intestine (NRI), TOMOSIB showed borderline superiority only in NRI toxicity (p=0.047). For the urinary toxicity, there was no significant difference between two groups (p=0.796). On dosimetric analysis for the rectum and bladder, dose delivered to 80% (p<0.001) and volume receiving 25-40 Gy (p<0.001) were remarkably higher in 3DCRT. For the NRI, only maximum dose showed significant results between two groups (p<0.001). Conclusion Intestinal toxicity should be verified with more detailed anatomic categorization such as rectum and NRI. TOMOSIB could not reduce urinary toxicity because of inevitably high dose exposure to the prostatic urethra. Current dosimetry system did not properly reflect intestinal/urinary toxicity, and suitable dosimetric guidelines are needed in TOMOSIB.
    Yonsei Medical Journal 02/2015; 56(2):510-518. DOI:10.3349/ymj.2015.56.2.510 · 1.26 Impact Factor
  • JAIDS Journal of Acquired Immune Deficiency Syndromes 01/2011; 56:97. DOI:10.1097/01.qai.0000397407.14534.2e · 4.39 Impact Factor


Available from